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A C C E P T E D M A N U S C R I P T 4 intriguing in light of the fact that FGFBP1 was found to bind near the FGF7 binding site of perlecan, an HSPG with important roles at synapses [22] [23] [24] . However, FGFBPs appear to displace rather than pluck away FGF7 from perlecan. Biochemical studies have also shown that FGFBPs and heparin and heparan sulfate do not simultaneously bind to FGFs [9, 25] . Thus, there is no evidence that FGFBPs bind and release FGFs associated with HSPGs. In a second model, FGFBPs instead bind to FGFs following their release into the ECM from HSPGs by heparanases, sulfatases and proteinases (Fig. 2b) . In this case, it is plausible that chaperoning FGFBPs serve to protect FGFs from proteolysis during their migration to FGF receptors (FGFRs) . In a third model, FGFBPs bind to FGFs immediately after being secreted from cells, and thus prior to interacting with HSPGs ( Fig. 2c) . Each of these models is possible when considering the evidence that FGFBPs compete with heparin for FGF binding [9, 22] , as well as the literature suggesting that HSPGs serve as a reservoir for and prevent the degradation of FGFs [7, 8, 26] .
FGFBPs may modulate FGF-signaling through additional mechanisms. For example, the heparin-and FGF-binding domains may allow FGFBPs to participate in the secretion of FGFs together with other proteins. FGF1 and FGF2 lack a signal peptide, and are not secreted through the endoplasmic reticulum/Golgi pathway and therefore require unique assistance by cell surface proteins for secretion [8] . In the case of FGF1, a heparin-binding complex composed of synaptotagmin 1 and S100A13 assists in its secretion [27] . FGF2 requires direct interaction with cell-surface HSPGs, such as perlecan, for secretion into the ECM [22, [28] [29] [30] . In either case, it is possible that FGFBPs could interact with these protein complexes via its heparin-binding domain and with FGF1/2 through its FGF-binding domain to assist in the secretion of FGF1/2. Additionally, FGFBPs may alter the relationship between FGFs and FGFRs, and thereby impact varied biological processes. FGF1/2 bind and activate all FGFRs and their splice variants, and FGF7/10/22 only bind and activate splice variants 2b of FGFR1 and FGFR2 [10, 31] . To date, it remains unknown if FGFBP1 affects the affinity of FGF1/2 to the b-isoforms of FGFRs, or possibly allow FGF7/10/22 to bind and activate additional FGFR isoforms, such as the cisoform. Lastly, FGFBPs may cooperate with HSPGs to augment FGFs availability at sites populated by preferred and non-preferred FGFRs. During development, cells expressing FGFR2b tend to express FGF ligands with specificity to FGFR2c, while cells expressing the cisoform express FGF ligands specific to the b-isoform [32, 33] . This pattern of expression makes it possible for neighboring cells to coordinate their differentiation. If present, FGFBPs may be
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A N U S C R I P T 5 utilized to adjust levels of FGF-signaling necessary for the differentiation of each cell type. In adulthood, FGFBPs may function to alter the bioavailability and binding of FGF ligands to different FGFRs, and thereby allow FGF secreting cells to affect several different cell types.
Through these potential modes of actions, expression pattern and interaction with HSPGs, FGFBPs may further modulate FGF-signaling to ensure the proper formation, stability and repair of neuronal and other tissues.
FGFBPs actions in the peripheral nervous system (PNS):
Recent studies, including from our group, have examined the expression and function of FGFBP1 at neuromuscular junctions (NMJs), the synapse formed between α-motor neurons and extrafusal muscle fibers. These studies uncovered important functions for FGFBP1 in the development, maintenance and repair of NMJs. In addition, FGF ligands known to interact with FGFBPs are known to play diverse and critical roles in the PNS. Hence, FGFBPs have been implicated in modulating a variety of biological processes in the PNS, which are discussed in this section.
FGFBPs at developing NMJs:
The formation and stability of the NMJ requires instructive molecular signals secreted by muscle fibers and innervating motor axons. FGF7/10/22, ligands shown to bind FGFBP1 [10] , are among muscle-derived soluble signaling factors proposed to act to ensure the timely maturation of the presynaptic region (motor axon nerve ending responsible for secreting neurotransmitters) at the NMJ during development [34] [35] [36] . These ligands act through the FGF receptor 2 (FGFR2), located on the presynaptic membrane, to promote the clustering of synaptic vesicles. Demonstrating the importance of this signaling module in the development of NMJs, deletion of FGFR2 has been shown to delay the timely clustering of synaptic vesicles in the presynaptic site of developing NMJs [37] . FGF2, a ligand through which both rodent FGFBPs are known to act, has also been found to play important roles at developing NMJs by activating FGFR1 following its release from muscles and motor neurons. Recombinant FGF2 increases the clustering of synaptic vesicles, an early cellular change at developing NMJs, when added to cultured motor neurons [38] .
Additionally, FGF2 is important for the timely elimination of supernumerary axons innervating a single muscle fiber, a term often referred to as "synaptic elimination" [39] [40] [41] . In mice and rats, synaptic elimination ends around nine postnatal days (P9), but injection of FGF2 into rat
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A C C E P T E D M A N U S C R I P T 6 gastrocnemius muscles at P2 slows the rate of synaptic elimination, and muscle fibers remain innervated by multiple motor axons until P14 [40] . However, another study found a contrary phenotype. Seitz and colleagues [42] showed that deleting FGF2 in mice slows the rate of synaptic elimination. While these published data appear to contradict each other, it is worth noting that the first study injected FGF2 during synapse elimination while in the second study, FGF2 was deleted in the germ line, and thus globally and permanently. It is therefore plausible that the levels of FGF2 at specific stages of development and secreted from unique cell types have different effects on the development of NMJs. In this regard, FGF2 levels have been found to correlate with different cellular changes associated with synaptic elimination [41] , such as the arrival of the growing motor axon, the differentiation of the motor axon growth cone into a presynaptic site, and the reduction of nerve sprouts that migrate beyond the postsynaptic site. In addition to affecting the presynaptic region of the NMJ, FGF2 also affects the development of the postsynaptic region. Specifically, FGF2 was found to induce the aggregation of nicotinic acetylcholine receptors (nAChRs), which are responsible for receiving and decoding cholinergic transmission derived from innervating α-motor axons [43] . Although the impact of FGF2 on NMJ development and maturation is broad and somewhat contradictory, what is clear is that FGF2 function must be closely regulated. Thus, it is plausible that FGFBPs may play a key role in regulating the actions of FGF2 at developing NMJs.
Among FGFBPs, there is growing evidence to suggest that FGFBP1 promotes presynaptic maturation of developing NMJs, possibly through its interaction with FGF7/10/22. FGFBP1 enhances the ability of FGF10 to induce aggregation of synaptic vesicles along neurites in cultured motor neurons [44] . In vivo, decreasing FGFBP1 using interfering RNA delays the aggregation of synaptic vesicles at presynaptic sites and reduces the size of the postsynaptic region at developing NMJs [36] . Additionally, we recently demonstrated that deletion of FGFBP1 delays the aggregation of synaptic vesicles at the presynapse and slows synaptic competition at the developing NMJ in mice [45] . In light of previous findings characterizing the role of FGF7/10/22 in orchestrating presynaptic maturation [34, 37] , we propose that FGFBP1 may work in concert with these ligands at developing NMJs. Interestingly, FGFBP1 expression is relatively low in developing compared to adult skeletal muscles. In stark contrast, FGF7/10/22 are expressed at high levels early in development but decrease as skeletal muscles and their NMJs mature [44, 46] . This anti-correlated expression pattern suggests that FGFBP1 may not
have a major effect on FGF-signaling in the early stages of NMJ maturation but may become increasingly important during the later stages of NMJ maturation.
In addition to the high levels of FGF ligands during the earlier stages of NMJ development, the presynaptic and postsynaptic regions are in very close proximity during this time [47] . We propose that this architectural design could make it more feasible for FGFs to reach and activate FGFRs located in opposite membranes without the aid of FGFBPs (Fig. 3) . Additionally, the short distance between the presynaptic and postsynaptic regions at developing NMJs may increase the possibility that FGFs bound to HSPGs will directly activate FGFRs (Fig. 3) . The extracellular space separating the NMJ is referred to as the synaptic cleft, which is relatively small early in development but increases to become approximately 50 nm wide [47] in adulthood Additionally, FGF7 has been found to bind to perlecan, an interaction that may aid in its synaptogenic activity [29, 54] . Based on these data, we propose that FGFBPs may be less important for FGFs to promote the initial maturation of the NMJ (Fig. 3a) . However, as levels of FGFs decrease and the synaptic cleft widens during the late stages of NMJ maturation ( Fig. 3bc ), appropriate levels of FGF-signaling may be bolstered by a concomitant increase in FGFBP1 expression in skeletal muscles [45] .
FGFBPs at adult NMJs:
In skeletal muscles, FGFBP1 was initially discovered as a factor utilized by a microRNA, miR-206, to promote reinnervation of previously vacated postsynaptic sites following injury and in amyotrophic lateral sclerosis (ALS) [36, 55] . Recently, we demonstrated important roles for FGFBP1 at NMJs during normal aging and in the SOD1 G93A mouse model for ALS [45] . Similar to miR-206, FGFBP1 is enriched at the endplate region, where NMJs are located, of skeletal muscles in healthy adult mice. However, FGFBP1 expression decreases at the endplate region and elsewhere in skeletal muscles with advancing
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age. FGFBP1 expression also decreases in skeletal muscles of SOD1 G93A mice prior to obvious morphological changes at NMJs and outward pathological symptoms that resemble those in human patients with the disease. While FGFBP1 expression decreases, the synaptic cleft likely further widens in part due to excess deposition of ECM proteins in aged and ALS-affected skeletal muscles [56, 57] . In light of this, we hypothesize that a combination of decreased expression of FGFBP1 and changes in the ECM results in diminished FGF-signaling, which may be a contributing factor to the pathophysiological features that accrue with advancing age and progression of ALS in skeletal muscles. In support of this hypothesis, we recently showed that deletion of FGFBP1 accelerates age-related degeneration of NMJs and alters expression of genes critical for the function of the NMJ and involved in muscle atrophy. We also found that FGFBP1 is required to slow the degeneration of ALS-affected NMJs [45] . Loss of FGFBP1 accelerates the degeneration of NMJs in SOD1 G93A mice, and shortens their lifespan. These published findings demonstrate that FGFBP1 plays important roles in the development and maintenance of NMJs.
Regulation of FGFBP1 expression in skeletal muscles and NMJs:
Since FGFBP1 is important for slowing the degeneration of NMJs, it is critical to understand the molecular mechanisms that inhibit FGFBP1 expression in aged and ALS-affected skeletal muscles. The TGF-β pathway is a prime candidate for inhibiting FGFBP1 expression in skeletal muscles.
TGF-β has been shown to repress FGFBP1 expression in mesenchymal and neural crest cells as they differentiate into smooth muscles [58] . In addition, TGF-β inhibits expression of the Krüppel-like factor 15 (KLF15) transcription factor, which is required for FGFBP1 expression in skeletal muscles [59] . The TGF-β pathway is also known to drive muscle atrophy with advancing age and in ALS [60], two conditions in which FGFBP1 expression decreases. It is therefore not surprising that TGF-β and FGFBP1 levels are anti-correlated in skeletal muscles of developing, healthy young adult, ALS-affected, and aged mice [45] . Demonstrating a direct relationship between TGF-β and FGFBP1 in skeletal muscles, TGF-β inhibits FGFBP1 expression when added to cultured myotubes. Supporting the notion of a direct effect, SB-431542, a small pharmacological agent that blocks the activity of the TGF-β type I receptor, prevents TGF-β from inhibiting FGFBP1 expression in cultured myotubes. TGF-β was also found to accumulate at the synaptic cleft of NMJs in degenerating skeletal muscles. This finding suggests that TGF-β
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inhibits FGFBP1 in the synaptic region of stressed skeletal muscles. In support of this possibility, TGF-β was shown to inhibit the miR-206/HDAC4 signaling axis, which concentrates at the NMJ and modulates FGFBP1 expression [36, 58, 61, 62] .
Unanswered questions regarding FGFBPs in the PNS: The role of FGFBP1 in repairing
NMJs remains unexplored in healthy adult skeletal muscles. This is despite the fact that FGFBP1 was discovered as a factor that miR-206, a synaptically-enriched microRNA, utilizes to promote reinnervation of muscle fibers, and thus reconstitution of whole NMJs [36] . It also remains unknown if FGFBPs augment the ability of FGF1 and FGF2 to induce the growth of peripheral nerves during both development and following injury [63] [64] [65] . Although not a focus of this review, FGFBPs may also play important functions in myogenesis during development, aging and progression of diseases. Among FGFBP ligands, FGF1 and FGF2 have been shown to affect the proliferation and differentiation of muscle satellite cells [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . While these FGF ligands promote myogenesis during development, FGF signaling does not necessarily confer the same benefits to the myogenic capacity of aged muscle [66] , and this may be due in part to the development of age-related changes in ECM composition [76] . The ECM has also been shown to change in diseases that affect skeletal muscles, such as the spectrum of muscular dystrophies [77] . These are conditions where FGFBPs would presumably be most beneficial for myogenesis as well as for the NMJ given their ability to release FGFs from the ECM, and thus promote FGFsignaling. However, the expression of FGFBPs in aged and muscular dystrophy-affected skeletal muscles remains largely unexplored. While we recently showed that FGFBP1 decreases in skeletal muscles with advancing age [45] , FGFBP1 expression in skeletal muscle afflicted with muscular dystrophy has yet to be determined. There is even less known regarding levels and function of FGFBP3 in healthy, aged and disease-affected skeletal muscles and their NMJs. If decreased, the loss of FGFBPs could impair the ability of FGFs to traverse the ECM, and thus induce myogenesis. Additionally, it is imperative to determine if FGFBPs bind to additional secreted FGF ligands, such as FGF6 that are known to play key roles in skeletal muscles [8, 78, 79] and elsewhere in the PNS. These questions will need to be addressed to better understand the roles of FGFBPs in developing, adult and stressed skeletal muscles, NMJs, and peripheral nerves.
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T 10
Role of FGFBPs and their binding partners in the central nervous system (CNS):
To date, there is little information regarding the expression and function of FGFBPs in the CNS. In one study, FGFBP3 was found expressed at high levels in the brain during development but decreased in the brain of adult mice. This study also showed that FGFBP3 is primarily expressed by neurons [12] . Importantly, it demonstrated that deletion of FGFBP3 reduces neuronal activity in the orbitofrontal cortex, causing anxiety-like behaviors. Recently, Schmidt et al. revealed that FGFBP1 may also play important roles in the CNS [80] . The authors performed a comprehensive analysis of mice lacking FGFBP1, detailed in the supplementary material of the publication, including behavioral and electrophysiological tests. They discovered that mice lacking FGFBP1 have altered auditory brain stem response, a measure of hearing sensitivity in mice, and increased likelihood of falling off a rotarod before completion of the test even though the time spent on the rotarod was not significantly different. In an open field test, mice lacking FGFBP1 were less likely to enter, spent less time, and covered less distance within the center of the field.
These mice also exhibited a lower frequency of rearing compared to wild-type mice.
Interestingly, several of these behavioral alterations were more severe in female mice lacking FGFBP1. These studies thus indicate that FGFBPs play important functions in the CNS, and their loss contributes to neurological deficits.
The published findings described above suggest that FGFBPs are important for modulating the actions of FGFs involved in the wiring of neural circuits in the CNS. Consequently, there is a rich literature on the role of FGF1/2 and FGF7/10/22, FGFBP ligands, in synapse development, plasticity, and repair in the CNS [81] [82] [83] . Based on this, some inferences can be made about the potential roles of FGFBPs in the CNS due to their modulatory activity of FGF ligands. For example, FGF7/10/22 are intimately involved in promoting the formation and maturation of synapses in the CNS [35, 44, 83] . Neurons in the hippocampus, dorsal lateral geniculate nucleus (dLGN), cerebellum, and spinal cord release FGF22 to promote the formation of excitatory synaptic inputs [35, 84, 85] . In the dLGN, neurons secrete FGF22 to ensure the timely development of retinogeniculate synapses [84] . In the cerebellum, conditionally deleting FGFR2b, the main receptor for FGF7/10/22, at P0 reduces the size, number, and intensity of synapsin-positive vesicles during development [83] . In the spinal cord, relay neurons secrete FGF22 to promote the reformation of corticospinal inputs following injury [86] . FGF7, on the other hand, is critical for the formation of inhibitory synapses in the CNS. In the hippocampus,
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
11 pyramidal neurons release FGF7 to promote the formation of inhibitory synaptic inputs while also secreting FGF22 to promote the formation of excitatory synaptic inputs [35, 83, 87, 88] . These studies have established FGF7/10/22 as target-derived synaptic organizing molecules secreted by postsynaptic neurons to direct the formation and maturation of presynaptic sites [44] . They have also shown that FGF7 and FGF22 are necessary for establishing the correct ratio of excitatory to inhibitory synapses in the hippocampus. Consequently, it is possible that FGFBP1 may be involved in fine-tuning the excitatory-inhibitory balance during development, however the expression of FGFBP1 in the developing brain remains to be established.
In addition to the FGF7/10/22 family, FGF2 has also been well characterized for promoting the maturation of excitatory synapses in the developing hippocampus. FGF2 expression is widespread throughout the CNS, including the hippocampus, and it is present as early as embryonic day 9 in mice [89] [90] [91] . In the CNS, expression of FGF2 is found in both neuronal and non-neuronal cell types, including astrocytes. Its specific role in synaptic maturation was first demonstrated in vitro by Li and colleagues [92] , where treatment of cultured rat hippocampal neurons with recombinant FGF2 resulted in an overall increased number of presynaptic synaptophysin-and synapsin I-positive puncta, as well as postsynaptic PSD95-and GluR1positive puncta. In addition to influencing pre-and postsynaptic maturation, treatment with recombinant FGF2 increased synapse formation, as an overall increase in colocalized synaptophysin-GluR1 puncta was observed. Functional analysis using potassium stimulation demonstrated that the FGF2-induced increase in synapses were likely functional as no differences in the percent of active synapses were observed between FGF2 treated and control groups. Subsequent in vivo work added further support for the role of FGF2 in synapse formation [93] . Using transgenic mice that overexpress FGF2, increased VGluT1, but not VGAT or GABA levels were observed in the hippocampus by immunohistochemistry. This was accompanied by observations of elevated glutamate release following single cell stimulation of Schaffer collaterals in the hippocampus of FGF2 transgenic mice as well as increased susceptibility to kainate-induced seizures [46] . Together, these results demonstrate a clear role for FGF2 in specifically promoting the formation of glutamatergic synapses and may have important implications for FGFBPs in the developing hippocampus.
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Although there are no reports that FGF1 plays roles in synapse formation in the brain directly, it should be noted that FGF1 is present throughout the developing rodent brain and spinal cord with expression beginning near E11 in mouse and has been implicated in synaptic plasticity [91, 94] . In addition, FGF1 is primarily expressed by neuronal cell types in the CNS [95] . Within neurons, FGF1 is localized to the cytoplasmic side of the extracellular membrane [96] . The presence of FGF1 at the extracellular membrane of neurons in the developing brain suggests an unexplored role of FGF1 in the neuronal development or the establishment of neural circuits, which includes the formation of synapses. These discoveries along with findings that various HSPGs, such as perlecan, play important functions in the CNS suggest that secretion of FGFBPs is important for modulating the synaptogenic actions of FGF ligands.
FGFBPs role in CNS pathology:
As central modulators of FGF signaling with known roles at the NMJ, it is reasonable to posit that FGFBPs play important functions in the CNS during the progression of diseases, including with advancing age and following injury. Accordingly, Bachis et al. [97] found that both FGF2 and FGFBP1 levels increase in the brains of rats treated with antidepressants. Specifically, they found that FGFBP1 remains increased in the cortex and hippocampus two weeks following treatment with desipramine or fluoxetine, which are norepinephrine and serotonin reuptake inhibitors, respectively. The sustained increase in FGFBP1 suggests that it may be involved in modifying the structure and function of neural circuits following noradrenergic and serotonergic treatments, likely acting through FGF2 modulation. More recently, Yamanaka et al. showed that FGFBP3 is necessary to prevent changes in neural circuits that cause anxiety-like behaviors [12] , and loss of FGFBP1 results in behavioral and electrophysiological alterations in mice [80] . Supporting these and other roles for FGFBPs in the CNS, FGF7 and FGF22 are critical for establishing the correct ratio of excitatory to inhibitory synapses, and disrupting their function alters the threshold for neuronal activity associated with epileptogenic seizures [35, 87, 98] . Moreover, a wealth of evidence has been accumulated demonstrating the importance of FGF1/2, FGF7/10/22 and HSPGs in long-term potentiation, neurogenesis, and neuronal migration in the developing and adult brain [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] as well as in CNS disorders and injury [46, 106, [115] [116] [117] [118] [119] [120] [121] . In the spinal cord, Tassi et al. [122] demonstrated that FGFBP1 is upregulated at the lesion site of injured rat spinal cords. Their study also provided strong evidence that FGFBP1 works in concert with FGFs to promote the
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13 regeneration of axons in the injured spinal cord. Together, these published findings indicate that FGFBPs likely mediate a variety of cellular processes critical for preventing and repairing damages that occur in the CNS.
Conclusion and final remarks
Data have accrued indicating important functions of FGFBPs in the nervous system. 
